ArQule Inc. (ARQL)

3.38
NASDAQ : Health Technology
Prev Close 3.38
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.27 / 7.21
Avg Volume 1.23M
Exchange NASDAQ
Shares Outstanding 108.99M
Market Cap 374.94M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ArQule To Host Analyst Call Highlighting Clinical Progress From Ongoing Phase 1 Study Of Reversible BTK Inhibitor, ARQ 531, In Patients With Relapsed/Refractory Hematologic Malignancies

ArQule To Host Analyst Call Highlighting Clinical Progress From Ongoing Phase 1 Study Of Reversible BTK Inhibitor, ARQ 531, In Patients With Relapsed/Refractory Hematologic Malignancies

ArQule, Inc. (Nasdaq: ARQL) today announced that it will host a call to discuss the updated safety, PK, biomarker and anti-tumor activity data from the company's Phase 1 dose escalation study in patients with relapsed or refractory hematologic...

ArQule To Present Clinical Data For Its BTK Inhibitor, ARQ 531, At The 2018 American Society Of Hematology (ASH) Annual Meeting

ArQule To Present Clinical Data For Its BTK Inhibitor, ARQ 531, At The 2018 American Society Of Hematology (ASH) Annual Meeting

ArQule, Inc. (Nasdaq:ARQL) today announced that it will present clinical data on the company's BTK inhibitor, ARQ 531, in a poster presentation at the 60 th American Society of Hematology (ASH) Annual Meeting and Exposition to be held from December 1 to...

ArQule Presents Clinical And Preclinical Data For ARQ 751 At The 30th EORTC/AACR/NCI Symposium

ArQule Presents Clinical And Preclinical Data For ARQ 751 At The 30th EORTC/AACR/NCI Symposium

ArQule, Inc. (Nasdaq: ARQL) today announced the presentation of clinical and preclinical data on ARQ 751 in three poster presentations at the 30th EORTC/AACR/NCI Symposium held from November 13 to 16, 2018 in Dublin, Ireland.

ArQule To Present At The 30th Annual Piper Jaffray Healthcare Conference On November 28, 2018

ArQule To Present At The 30th Annual Piper Jaffray Healthcare Conference On November 28, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President, Head of Strategy, Finance, and Communication will present at the 30th Annual Piper Jaffray Healthcare Conference on November...

ArQule To Present Clinical And Preclinical Data For ARQ 751 At The 30th EORTC/AACR/NCI Symposium

ArQule To Present Clinical And Preclinical Data For ARQ 751 At The 30th EORTC/AACR/NCI Symposium

ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting clinical and preclinical data on the company's next generation AKT inhibitor, ARQ 751, in three poster presentations at the 30th EORTC/AACR/NCI Symposium to be held from November 13 to...

ArQule Reports Third Quarter 2018 Financial Results

ArQule Reports Third Quarter 2018 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2018.

ArQule Presents Orphan Disease Clinical Data At The American Society Of Human Genetics (ASHG) 2018 Annual Meeting For Its Pan-AKT Inhibitor, Miransertib (ARQ 092)

ArQule Presents Orphan Disease Clinical Data At The American Society Of Human Genetics (ASHG) 2018 Annual Meeting For Its Pan-AKT Inhibitor, Miransertib (ARQ 092)

ArQule, Inc. (Nasdaq:ARQL) today announced the presentation of preliminary clinical data on miransertib (ARQ 092) in three poster presentations at the American Society of Human Genetics (ASHG) 2018 Annual Meeting held from October 16 to 20, 2018 in San...

ArQule To Report Third Quarter 2018 Financial Results On October 31, 2018

ArQule To Report Third Quarter 2018 Financial Results On October 31, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter of 2018 before the market opens on Wednesday, October 31, 2018.

ArQule Becomes Oversold (ARQL)

ArQule Becomes Oversold (ARQL)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

ArQule To Present Clinical Update For Miransertib In Rare Disease At The American Society Of Human Genetics (ASHG) 2018 Annual Meeting

ArQule To Present Clinical Update For Miransertib In Rare Disease At The American Society Of Human Genetics (ASHG) 2018 Annual Meeting

ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting clinical data on the company's lead AKT inhibitor, miransertib (ARQ 092), in three poster presentations at the American Society of Human Genetics (ASHG) 2018 Annual Meeting to be held...

ARQL: Insiders Vs. Shorts

ARQL: Insiders Vs. Shorts

The most recent short interest data was recently released for the 09/14/2018 settlement date, and ArQule Inc. is one of the most shorted stocks of the Russell 3000, based on 6.65 "days to cover" versus the median component at 5.36.

ArQule To Present At The Leerink Partners Roundtable Series: Rare Disease & Oncology On October 2, 2018

ArQule To Present At The Leerink Partners Roundtable Series: Rare Disease & Oncology On October 2, 2018

ArQule, Inc. (Nasdaq:ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, Dr.

ArQule To Present At The Cantor Global Healthcare Conference On October 1, 2018

ArQule To Present At The Cantor Global Healthcare Conference On October 1, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President, Strategy, Communication and Finance, will present at the Cantor Global Healthcare Conference on October 1, 2018, at 2:55pm ET...

Miransertib (ARQ 092) Granted Fast Track Designation For The Treatment Of PIK3CA-Related Overgrowth Spectrum (PROS)

Miransertib (ARQ 092) Granted Fast Track Designation For The Treatment Of PIK3CA-Related Overgrowth Spectrum (PROS)

ArQule, Inc. (Nasdaq: ARQL) today announced that the U.

ArQule To Participate In Citi's 13th Annual Biotech Conference On September 6, 2018

ArQule To Participate In Citi's 13th Annual Biotech Conference On September 6, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, CEO, Peter Lawrence, President and COO, Brian Schwartz, CMO and Head of R&D and Marc Schegerin, Senior Vice President and Head of Strategy, Finance and Communication, will participate in Citi's...

ArQule To Participate In The Annual B. Riley FBR Healthcare Conference On September 4, 2018

ArQule To Participate In The Annual B. Riley FBR Healthcare Conference On September 4, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, CEO, and Dr.

ArQule To Present At The 20th Annual Global Investment Conference On September 5, 2018

ArQule To Present At The 20th Annual Global Investment Conference On September 5, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President, Strategy, Communication and Finance, will present at the 20 th Annual Rodman & Renshaw Global Investment Conference,...

First Week Of April 2019 Options Trading For ArQule (ARQL)

First Week Of April 2019 Options Trading For ArQule (ARQL)

Investors in ArQule Inc. saw new options begin trading this week, for the April 2019 expiration.

ArQule Announces Publication Of Preclinical Data For ARQ 531, A Reversible Inhibitor Of Both Wild Type And Mutant BTK

ArQule Announces Publication Of Preclinical Data For ARQ 531, A Reversible Inhibitor Of Both Wild Type And Mutant BTK

ArQule, Inc. (Nasdaq:ARQL), today announced the publication of preclinical study data for ARQ 531, the Company's rationally-designed, reversible inhibitor of both wild type and C481S-mutant Bruton's tyrosine kinase (BTK).

ArQule Reports Second Quarter 2018 Financial Results

ArQule Reports Second Quarter 2018 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2018.

First Week Of September 21st Options Trading For ArQule (ARQL)

First Week Of September 21st Options Trading For ArQule (ARQL)

Investors in ArQule Inc. saw new options begin trading this week, for the September 21st expiration.

ArQule To Report Second Quarter 2018 Financial Results On August 1, 2018

ArQule To Report Second Quarter 2018 Financial Results On August 1, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the second quarter of 2018 before the market opens on Wednesday, August 1, 2018.

ArQule Announces Closing Of Public Offering And Full Exercise Of Option To Purchase Additional Shares

ArQule Announces Closing Of Public Offering And Full Exercise Of Option To Purchase Additional Shares

ArQule, Inc. (Nasdaq: ARQL) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,650,000 shares at the public...

ArQule Announces Pricing Of $60.5 Million Public Offering Of Common Stock

ArQule Announces Pricing Of $60.5 Million Public Offering Of Common Stock

ArQule, Inc. (Nasdaq: ARQL) today announced the pricing of an underwritten public offering of 11 million shares of its common stock at a price to the public of $5.

ArQule Announces Commencement Of Proposed Public Offering Of Common Stock

ArQule Announces Commencement Of Proposed Public Offering Of Common Stock

ArQule, Inc. (Nasdaq: ARQL) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock.

ArQule Added To The Russell 2000® Index

ArQule Added To The Russell 2000® Index

ArQule, Inc. (Nasdaq: ARQL) today announced that it has been added to the Russell 2000 ® Index, a subset of the Russell 3000 ® Index, effective as of market closing on June 22, 2018, at the conclusion of the annual Russell US Index reconstitution.

ArQule Presents Results From Ongoing Phase 1 Dose Escalation Study Of Its Reversible BTK Inhibitor, ARQ 531

ArQule Presents Results From Ongoing Phase 1 Dose Escalation Study Of Its Reversible BTK Inhibitor, ARQ 531

ArQule, Inc. (Nasdaq:ARQL) today is presenting preliminary results from the Company's Phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton's tyrosine kinase (BTK) in...

ArQule To Present At The JMP Securities Life Sciences Conference On June 21, 2018

ArQule To Present At The JMP Securities Life Sciences Conference On June 21, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr.

TheStreet Quant Rating: D (Sell)